TCR2 Therapeutics Inc. announced three new management appointments as the company advances its TRuC™-T cell programs toward the clinic to address solid tumors. Alfonso Quintás Cardama was named as the company's first Chief Medical Officer. In this role, he will be responsible for clinical and regulatory strategies as TCR2 transitions into a clinical-stage company with lead program TC-210 during 2018. In addition, TCR2 strengthened its senior team with the appointments of Andrew Cornforth as Vice President of Process Development and Daniel Getts as Vice President of Research. Alfonso Quintás Cardama, TCR2's new Chief Medical Officer, brings nearly 20 years of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. He joins TCR2 from GlaxoSmithKline where he was clinical development head of the Cell & Gene Therapies Unit and responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on the affinity enhanced T-cell therapies. Previously, Alfonso served as Global Clinical Leader of Novartis's recently approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Daniel Getts, TCR2's Vice President of Research, is responsible for target discovery, preclinical research and translational sciences. Previously, he was co-founder and Chief Scientific Officer of Cour Pharmaceuticals, a nanotechnology company focused on immune disorders. He also served as Director, Research & Development at Tolera Therapeutics where he was responsible for advancing the company's monoclonal antibody program.